CA 494—a new tumor marker for the diagnosis of pancreatic cancer
| Autor: | Norbert Madry, K. Bosslet, Kai Hammer, Markus W. Büchler, Alexander Weber, Bernhard Dr Auerbach, Peter Malfertheiner, Helmut Friess, Sabine Greiner, Hans G. Beger |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Pancreatic disease Adolescent CA 15-3 Sensitivity and Specificity Antigen Pancreatic cancer Biomarkers Tumor Diabetes Mellitus Humans Medicine Antigens Tumor-Associated Carbohydrate Aged Tumor marker Aged 80 and over business.industry Pancreatic Diseases Middle Aged medicine.disease Carcinoembryonic Antigen Pancreatic Neoplasms medicine.anatomical_structure Oncology Pancreatitis Female CA19-9 business Pancreas |
| Zdroj: | International Journal of Cancer. 53:759-763 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.2910530509 |
| Popis: | In 59 patients with ductal pancreatic cancer the monoclonal antibody (MAb) BW 494, which detects the CA 494 glycoprotein antigen, was analyzed in comparison with the reference tumor markers CA 19-9 and CEA. Eighty-one patients with non-pancreatic malignancies of the gastrointestinal (GI) tract, 95 with chronic pancreatitis, 124 with benign non-pancreatic GI diseases, 30 with diabetes mellitus (type I or type II) and 114 healthy blood donors served as controls. The sensitivity of pancreatic cancer was 90%, 44% and 90% for CA 19-9, CEA and CA 494, respectively. In chronic pancreatitis, as the most important control population for pancreatic cancer, the specificity was 85%, 72% and 94% for CA 19-9, CEA and CA 494, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text